Toll Free: 1-888-928-9744
Published: May, 2015 | Pages:
43 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015 Summary Global Markets Direct's, 'Herpes Labialis (Oral Herpes) - Pipeline Review, H1 2015', provides an overview of the Herpes Labialis (Oral Herpes)'s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Herpes Labialis (Oral Herpes), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Labialis (Oral Herpes) and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Herpes Labialis (Oral Herpes) - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Herpes Labialis (Oral Herpes) and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Herpes Labialis (Oral Herpes) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Herpes Labialis (Oral Herpes) pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reason to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Herpes Labialis (Oral Herpes) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Herpes Labialis (Oral Herpes) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Herpes Labialis (Oral Herpes) Overview 6 Therapeutics Development 7 Pipeline Products for Herpes Labialis (Oral Herpes) - Overview 7 Pipeline Products for Herpes Labialis (Oral Herpes) - Comparative Analysis 8 Herpes Labialis (Oral Herpes) - Therapeutics under Development by Companies 9 Herpes Labialis (Oral Herpes) - Pipeline Products Glance 10 Late Stage Products 10 Clinical Stage Products 11 Early Stage Products 12 Herpes Labialis (Oral Herpes) - Products under Development by Companies 13 Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development 14 Beech Tree Labs, Inc. 14 Foamix Pharmaceuticals Ltd. 15 Mymetics Corporation 16 NanoViricides, Inc. 17 Onxeo SA 18 Spider Biotech 19 Herpes Labialis (Oral Herpes) - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 acyclovir - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 acyclovir - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Aspidasept - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 BTL-TMLHSV - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 HerpeCide-I - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 herpes simplex virus [type 1, 2] vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 SB-105A10 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Herpes Labialis (Oral Herpes) - Recent Pipeline Updates 37 Herpes Labialis (Oral Herpes) - Dormant Projects 40 Herpes Labialis (Oral Herpes) - Discontinued Products 41 Appendix 42 Methodology 42 Coverage 42 Secondary Research 42 Primary Research 42 Expert Panel Validation 42 Contact Us 42 Disclaimer 43
List of Tables
Number of Products under Development for Herpes Labialis (Oral Herpes), H1 2015 7 Number of Products under Development for Herpes Labialis (Oral Herpes) - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Herpes Labialis (Oral Herpes) - Pipeline by Beech Tree Labs, Inc., H1 2015 14 Herpes Labialis (Oral Herpes) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 15 Herpes Labialis (Oral Herpes) - Pipeline by Mymetics Corporation, H1 2015 16 Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides, Inc., H1 2015 17 Herpes Labialis (Oral Herpes) - Pipeline by Onxeo SA, H1 2015 18 Herpes Labialis (Oral Herpes) - Pipeline by Spider Biotech, H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 28 Herpes Labialis (Oral Herpes) Therapeutics - Recent Pipeline Updates, H1 2015 37 Herpes Labialis (Oral Herpes) - Dormant Projects, H1 2015 40 Herpes Labialis (Oral Herpes) - Discontinued Products, H1 2015 41
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.